Singapore markets closed
  • Straits Times Index

    3,092.11
    -6.14 (-0.20%)
     
  • S&P 500

    4,513.04
    -53.96 (-1.18%)
     
  • Dow

    34,022.04
    -461.68 (-1.34%)
     
  • Nasdaq

    15,254.05
    -283.64 (-1.83%)
     
  • BTC-USD

    56,638.80
    -394.95 (-0.69%)
     
  • CMC Crypto 200

    1,444.71
    -24.37 (-1.66%)
     
  • FTSE 100

    7,118.96
    -49.72 (-0.69%)
     
  • Gold

    1,776.10
    -8.20 (-0.46%)
     
  • Crude Oil

    66.91
    +1.34 (+2.04%)
     
  • 10-Yr Bond

    1.4340
    0.0000 (0.00%)
     
  • Nikkei

    27,753.37
    -182.25 (-0.65%)
     
  • Hang Seng

    23,788.93
    +130.01 (+0.55%)
     
  • FTSE Bursa Malaysia

    1,501.74
    +4.81 (+0.32%)
     
  • Jakarta Composite Index

    6,583.82
    +76.14 (+1.17%)
     
  • PSE Index

    7,032.54
    +85.48 (+1.23%)
     

Global Fuchs Endothelial Corneal Dystrophy Market to 2030 - Insights, Epidemiology and Forecasts - ResearchAndMarkets.com

·4-min read

DUBLIN, October 27, 2021--(BUSINESS WIRE)--The "Fuchs Endothelial Corneal Dystrophy (FECD) - Market Insights, Epidemiology, and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

This report delivers an in-depth understanding of the Fuchs Endothelial Corneal Dystrophy (FECD), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Fuchs Endothelial Corneal Dystrophy (FECD) market report provides current treatment practices, emerging drugs, and their market share of the individual therapies, current and forecasted Fuchs Endothelial Corneal Dystrophy (FECD) symptoms market size from 2018 to 2030 segmented by seven major markets. The report also covers current Fuchs Endothelial Corneal Dystrophy (FECD) symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities. It assesses the underlying potential of the market.

Fuchs Endothelial Corneal Dystrophy (FECD) Overview

Fuchs Endothelial Corneal Dystrophy (FECD) or Fuchs' endothelial dystrophy is a defect of the cornea of the eye, where endothelial cells degenerate/get damaged. It can be either sporadic or inherited in an autosomal dominant manner. Fuchs' dystrophy is characterized by the swelling of the cornea, which leads to glare, halo, and reduced visual acuity. In some cases, it can lead to corneal blindness.

FECD is characterized by an asymmetrical, bilateral, slowly progressive edema of the cornea in elderly patients and is more prominent in females than males. Deposits called guttae are generally detectable during an eye exam. They usually form in the middle of the cornea and eventually spread throughout the cornea. These guttae contribute to the ongoing cell death within the cornea, leading to worsening vision problems. Tiny blisters may develop on the cornea, which can burst and cause eye pain.

Fuchs Endothelial Corneal Dystrophy (FECD) Epidemiology

The Fuchs Endothelial Corneal Dystrophy (FECD) symptoms epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends and assumptions.

Key Findings

The total prevalent cases of Fuchs Endothelial Corneal Dystrophy (FECD) is increasing 7MM during the study period, i.e., 2018-2030.

The disease epidemiology covered in the report provides historical as well as forecasted Fuchs Endothelial Corneal Dystrophy (FECD) symptoms epidemiology segmented as the prevalent cases of Fuchs Endothelial Corneal Dystrophy (FECD), Gender-specific cases of Fuchs Endothelial Corneal Dystrophy (FECD), and Age-specific cases of Fuchs Endothelial Corneal Dystrophy (FECD). The report includes the prevalent scenario of Fuchs Endothelial Corneal Dystrophy (FECD) symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Scope of the Report

  • The report covers the descriptive overview of Fuchs Endothelial Corneal Dystrophy (FECD), explaining its causes, signs and symptoms, physiology, and currently available therapies.

  • Comprehensive insight has been provided into the Fuchs Endothelial Corneal Dystrophy (FECD) epidemiology and treatment in the 7MM.

  • Additionally, an all-inclusive account of both the current and emerging therapies for Fuchs Endothelial Corneal Dystrophy (FECD) is provided, along with the assessment of new therapies, which will impact the current treatment landscape.

  • A detailed review of the Fuchs Endothelial Corneal Dystrophy (FECD) market, historical and forecasted, is included in the report, covering drug outreach in the 7MM.

  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Fuchs Endothelial Corneal Dystrophy (FECD) market.

Report Highlights

  • In the coming years, the Fuchs Endothelial Corneal Dystrophy (FECD) market is set to change due to the rising awareness of the disease and the Favorable Environment for New Anti-infective Modalities; which would expand the market's size to enable the drug manufacturers to penetrate more into the market.

  • The companies and academics are working to assess challenges and seek opportunities that could influence Fuchs Endothelial Corneal Dystrophy (FECD) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.

  • Major players are involved in developing therapies for Fuchs Endothelial Corneal Dystrophy (FECD). The launch of emerging therapies will significantly impact the Fuchs Endothelial Corneal Dystrophy (FECD) market.

  • The in-depth analysis of the pipeline assets across different stages of development (Phase I, II, and III), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, and launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Companies Mentioned

  • Kowa Pharmaceuticals

  • Trefoil Therapeutics

  • ProQR Therapeutics

  • Emmecell

For more information about this report visit https://www.researchandmarkets.com/r/feurap

View source version on businesswire.com: https://www.businesswire.com/news/home/20211027005462/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting